LSIPR 50 2017: Stéphane Drouin—Innovation in a volatile climate

10-11-2017

LSIPR 50 2017: Stéphane Drouin—Innovation in a volatile climate

yulkapopkova / iStockphoto.com

Pharmaceutical company UCB injects a significant amount of revenue into R&D, but it is mindful of the risks attached to drug investment. Global head of IP Stéphane Drouin explains more in an interview with LSIPR.

“In the United States of America, healthcare is not a privilege for the fortunate few—it is a right,” Barack Obama said in 2013 when he spoke as President about the Patient Protection and Affordable Care Act, which had been signed into law in 2010.

The act, also known as ‘Obamacare’, aims to give more Americans access to affordable health insurance.

President Donald Trump is now trying to repeal Obamacare with the help of Republican lawmakers.


LSIPR 50 2017, Stéphane Drouin, External collaboration, R&D, neurology, immunology, UCB, Vimpat, innovative technology

LSIPR